On November 14-15, 2022, Dr. Yugang Guo, co-founder of Leman Biotech, was invited to participate in the 2022 World Science and Technology Youth Forum and the launch ceremony of the Global-Asia-Pacific Region's "35 Under 35 Science and Technology Innovation" by MIT Technology Review.
The 2022 World Science and Technology Youth Forum was held with the theme of "Seeing the Future". The conference was divided into five major sections, including "Endless Life" and "Game of Nature". These sections aimed to explore cutting-edge science and technology and innovative talents, as well as address the most pressing issues that impact the fate of humanity. The conference was a platform to discuss the latest trends in scientific and technological innovation, and the development of future innovative talents.
Dr. Yugang Guo, co-founder of Leman Biotech, was invited to give a keynote speech and participate in roundtable discussions with several academic and industrial leaders in the "Endless Life" section. He shared the superior performance and recent developments of Leman Biotech's core technology, Meta 10, in the field of solid tumor treatment. This helped bring new ideas for research and development of the next-generation of cancer immunotherapy.
Leman Biotech is a clinical-staged cancer immunotherapy company co-founded by Professor Li Tang of the Swiss Federal Institute of Technology in Lausanne (EPFL) and AI-driven drug R&D leader XtalPi. The company combines innovative metabolic reprogramming technology with cutting-edge AI drug discovery platform to develop next-generation cancer immunotherapies. The core technology Meta 10 has the potential to cure solid tumors, as demonstrated in the published research in the top academic journal Nature Immunology, and has PCT patents in 56 countries and regions, covering major economies in the world. The company has a highly qualified R&D team, with over 70% of its personnel having graduated from esteemed Chinese and international universities and holding extensive industrial experience. Several of Leman Biotech's R&D pipelines are in advanced stage of development, including a metabolically armed CAR-T cell therapy in IIT clinical research stage. In December 2021, just half a year after its inception, Leman Biotech completed a successful angel round of financing, raising nearly $11 million, with plans for further financing underway. Leman Biotech is committed to finding solutions to the bottlenecks in cancer immunotherapy, improving the response rate and efficacy, and making unremitting efforts to achieve the ultimate goal of curing cancer.
